

The association between plasma metabolites and sleep quality in the Southall and Brent Revisited Study (SABRE): A cross-sectional analysis.

Authors: Constantin-Cristian Topriceanu¹, Therese Tillin^{2,3}, Nishi Chaturvedi^{2,3}, Roshni Joshi², Victoria Garfield^{2,3}

Author Affiliations:

1. University College London Medical School, 74 Huntley St, Bloomsbury, London WC1E 6DE
2. Department of Population Science and Experimental Medicine, Institute of Cardiovascular Science, University College London, Gower Street, London, WC1E 6BT, UK.
3. MRC Unit for Lifelong Health and Ageing, University College London, 1-19 Torrington Place, London, WC1E 7HB

Corresponding author

Constantin-Cristian Topriceanu

Medical Student

University College London

74 Huntley St, Bloomsbury,

London WC1E 6DE

Email: zchatop@ucl.ac.uk, Phone no: +40 722217884

Conflict of Interest

The views expressed in this article are those of the authors who declare that they have no conflict of interest.

ABSTRACT

Background: Disordered metabolic processes have been associated with abnormal sleep patterns. However, the biological triggers and pathways are yet to be elucidated.

Methods: Participants were from the Southall and Brent REvisited (SABRE) cohort. Nuclear Magnetic Resonance spectroscopy provided 146 circulating plasma metabolites. Sleep questionnaires identified the presence or absence of: difficulty falling asleep (DFA), early morning waking (EMW), waking up tired (WUT) and snoring. Metabolites were compared between the sleep quality categories using the t-test, then filtered using a false discovery rate of 0.05. Generalized linear models with logit-link assessed the associations between filtered metabolites and sleep phenotypes. Adjustment was made for important demographic and health-related covariates.

Results: 2718 SABRE participants were included. After correcting for multiple testing, 3 metabolites remained for DFA, 59 for snoring and none for EMW and WUT. In fully-adjusted models, 1 standard deviation increase in serum histidine, leucine and valine associated with lower odds of DFA by 0.84-0.89 (95% confidence intervals [CIs]: 0.75-0.99). Branched chain amino acids (ORs 1.11-1.15, 95%CIs 1.01-1.26) were positively associated with snoring. Docosahexaenoic acid (DHA) (OR 0.89, 95% CI 0.82-0.96) and total cholesterol in low-density lipoprotein (LDL) (OR 0.89, 95% CI 0.82-0.96) and high-density lipoprotein (HDL) (ORs 0.90, 95% CIs 0.83-0.99) associated with lower odds of snoring.

Conclusion: Histidine, leucine and valine associated with lower odds of difficulty falling asleep, while docosahexaenoic acid and cholesterol LDL and HDL subfractions associated with lower odds of snoring. Identified metabolites could provide guidance on the metabolic pathways behind the adverse sleep quality.

Keywords

metabolites; lipoproteins; amino acids; difficulty falling asleep; snoring.

Key messages:

- Higher histidine, leucine and valine associate with lower odds of difficulty falling asleep.
- Branched amino acids (isoleucine, leucine and valine) were higher in participants experiencing snoring.
- Total cholesterol in LDL and HDL appeared to be beneficial in terms of snoring.

1. INTRODUCTION

Sleep is a vital component of the human circadian rhythm. Abnormal sleep patterns are increasingly common. Two of the most prevalent sleep disorders are insomnia and snoring, with recent estimates suggesting insomnia is reported in more than 30% and, snoring in more than 20% of the global population ¹.

Sleep is of primordial importance in physiological homeostasis. While adverse sleep phenotypes are associated with negative health consequences, including cardiovascular disease and cancer ², the triggers and pathways that may contribute to abnormal sleep phenotypes and related detrimental health outcomes have yet to be elucidated.

Metabolic dysfunction has been previously associated with sleep phenotypes ³. Insomnia and short sleep duration have been associated with increased odds of developing type 2 diabetes⁴, which could be mediated by branched chain amino acids⁵. Snoring has been associated with disordered metabolic processes including insulin resistance, hyperglycaemia and dyslipidemia (high triglycerides, high LDL cholesterol, low HDL cholesterol) ^{6,7}. However, the directionality of the association between metabolites and sleep phenotypes is still unclear, but it appears that disordered sleep may be both a cause and a consequence of abnormal metabolism.

Thus, using a metabolomics approach⁸ could lead to a better understanding of the mechanisms underlying abnormal sleep phenotypes as well as provide a direction for future novel guided therapies. Similar approaches have been successfully employed, for example in characterizing novel predictors for heart failure⁹.

In this cross-sectional study, Nuclear Magnetic Resonance (NMR) spectroscopy was used to identify metabolites that are associated with sleep phenotypes; difficulty falling asleep, early morning waking, waking up tired and snoring reported in participants from the Southall and Brent REvisited (SABRE) cohort.

2. METHODS

Participants and Study Design

The SABRE study is a tri-ethnic cohort of European, South Asian and African Caribbean participants living in West and North London (Southall and Brent districts). Between 1988-1991, participants aged between 40 to 69 years were randomly selected from 5-year age and sex stratified primary care lists (n=4.063) and workplaces (n=795). The full cohort details have been published elsewhere⁵. Ethnicity was self-assigned and agreed with the interviewer. South Asians and African Caribbeans were all first-generation migrants.

At baseline, participants were invited to a clinic appointment which involved completing a health and lifestyle questionnaire which included questions on sleep patterns. Fasting bloods were collected, and anthropometrics and blood pressure were measured. Diabetes was identified from self-report of physician diagnosis or receipt of anti-diabetes medications. In addition, oral glucose tolerance testing was performed. Undiagnosed diabetes was identified retrospectively using WHO 1999 criteria¹⁰.

The SABRE baseline study was granted ethics approval from Ealing, Hounslow and Spelthorne, Parkside and University College London research ethics committees.

Exposures

Exposures were NMR measured 146 circulating plasma metabolites including amino acids, small molecules (e.g. glycerol, pyruvate) and a detailed lipid profile consisting of 16 lipoprotein subclasses together with their lipid (phospholipids, triglycerides, total and free cholesterol, and cholesterol esters) component concentrations and particle dimensions.

Serum fasting samples were obtained from participants at baseline and for the Southall centre only (n=3700) were stored at -80°C. In 2012, a proton NMR spectrum was employed to detect circulating plasma metabolite levels following the signal suppression

of other molecules according to methodologies previously used¹¹. Ratios were excluded.

None of the study participants were receiving lipid-lowering medication at the time of the baseline studies.

Outcomes

The outcomes of interest were four sleep quality phenotypes: difficulty falling asleep, early morning waking, waking up tired and snoring.

Participants were asked to rate their sleep quality in the past 30 days at visit 1 (1988-90) using four questions adapted from the validated Jenkins Sleep Questionnaire (JSEQ)¹². They were asked whether they felt they had been waking up too early in the morning, had difficulties falling asleep at night, had problems with snoring during the night and whether they woke up feeling tired. All sleep phenotypes were rated binary (i.e. 'No'/0 or 'Yes'/1).

Covariates

Covariates were selected a priori based on prior associations with sleep quality and metabolism. Covariates were recorded at the time of the baseline studies (when serum samples were collected for storage) and included: age, sex, ethnicity, years of education, waist-hip-ratio (WHR), cardiovascular disease (CVD; coronary artery disease and stroke), Type 2 diabetes (T2DM), hypertension medication, total number of alcohol units per week and smoking status (never smoked, ex-smoker, current smoker). CVD, T2DM and hypertension medication were recorded as binary (yes/no).

Statistical methods

Data distribution was assessed graphically using histograms and statistically using the Shapiro-Wilk test. Continuous variables were expressed as medians (interquartile ranges), while categorical variables were expressed as counts (percentage). Metabolite concentrations were log-transformed, mean centered and scaled to a standard deviation (SD) of 1 before further analysis.

T-test analysis was used as a screening tool to identify metabolites linked with sleep phenotypes, correcting for multiple testing at a false discovery threshold of 0.05¹³. Metabolites that passed this threshold were further referred to as candidate metabolites. Candidate metabolite associations with sleep phenotypes were evaluated using multivariable generalized linear models accounting for age, sex, ethnicity and years of education (Model 1). Further adjustments were model 1 plus WHR, CVD, T2DM, anti-hypertensive medication, alcohol units and smoking status (model 2).

About a fifth of all participants reported zero weekly alcohol intake. To account for this high degree of zero-inflation,¹⁴ a modified version of GLM (using template model builder [glmmTMB]) was chosen (**Supplementary Note 1**). Thus, glmmTMB with binomial distribution and logit link (equivalent to logistic regression) using metabolites as exposures was employed to predict the binary sleep phenotypes as outcomes.

The T-test is not able to discriminate between groups where minor differences exist. This may not identify biologically relevant metabolites⁸. Thus, we ran the regression models for all the available metabolites as a sensitivity analysis.

Statistical analysis was performed in R (version-3.6.0)¹⁵. P-values <0.05 were considered significant.

3. RESULTS

PARTICIPANT CHARACTERISTICS

Of the 4,858 SABRE participants, 3,700 (from the Southall Centre only) had stored blood samples with 3,255 being viable for NMR analysis. Furthermore, 2,718 had all sleep phenotypes, covariates and metabolites. Of the 2,718 included participants, 23.79 (87.53%) were male and 664 (24.43%) were current smokers. The mean age of the cohort was 52 ± 7.18 and the mean WHR 0.95 ± 0.08 . Difficulty falling asleep was reported in 453 (16.67%) participants, early morning waking in 1,108 (40.77%), waking

up tired in 926 (34.11%) and snoring in 1051 (38.67%). Participants characteristics are summarized in **Table 1**.

SCREENING FOR CANDIDATE METABOLITES

Of the 146 available metabolites, 12 candidate metabolites were identified for difficulty falling asleep, 4 for early morning waking, 2 for waking up tired and 73 for snoring (**Supplementary Table S1**). After correction for multiple testing, histidine, leucine and valine remained for difficulty falling asleep. 59 metabolites were further considered as candidates in association with snoring. None remained for early morning waking and waking up tired (**Supplementary Table S1**).

DIFFICULTY FALLING ASLEEP

After adjusting for model 1, serum histidine, leucine and valine were inversely associated with difficulty falling asleep. In the fully-adjusted models, 1 SD increases in serum histidine, leucine and valine were associated with lower odds of difficulty falling asleep by odds ratio (OR) 0.89 (95% confidence interval [CI]: 0.80 to 0.99), 0.84 (95% CI 0.75 to 0.96), and 0.84 (0.75 to 0.94), respectively.

SNORING

Of 59 candidate metabolites associated with snoring, 31 remained associated with snoring in the fully-adjusted models (**Figure 1**). The odds ratios associated with 1SD increments in each of the 31 metabolites in Model 2 are presented in **Table 2** and visually illustrated in **Figure 2**. Amino acids and small molecules (e.g. acetate) were associated with higher odds of snoring. The largest positive estimate was observed for the aromatic amino acid, phenylalanine: OR 1.16 (95% CI 1.06-1.26). All branched-chain amino acids (BCCA) (isoleucine, leucine and valine) were associated with greater odds of snoring (OR in the range: 1.11-1.15). Serum lipids and lipoproteins (e.g. apolipoprotein (apo) A-I, docosahexaenoic acid, polyunsaturated fatty acids) (OR 0.88-0.92, 95% CIs 0.81-0.99) and total cholesterol in high-density lipoprotein (HDL) (OR 0.90, 95% CI 0.83-0.99) and in low-density lipoprotein (LDL) (OR 0.89, 95% CI 0.82-0.96) appeared to be beneficial. Regarding the subfraction breakdown, total cholesterol in

small HDL (OR 0.91, 95% CI 0.84-0.99) and in small, medium and large LDL (ORs 0.87-0.90, 95% CI 0.80-0.97) associated with lower odds of snoring. In addition, cholesterol-esters and phospholipids from certain LDL and HDL subfractions were also inversely associated with snoring (**Figure 2**), with the largest OR for lower odds of snoring being observed for cholesterol-esters in medium-LDL (OR 0.64, 95% CI 0.45-0.92).

SENSITIVITY ANALYSIS

Additional metabolites which were associated in the fully-adjusted models but did not pass the screening stage were identified (**Supplementary Table S2**). A 1SD increase in glycine, free cholesterol and sphingomyelins was related to greater odds (ORs \cong 1.15) of having difficulty falling asleep. Creatinine and valine were associated with lower odds (\cong 0.90) of early morning waking, while albumin and lactic acid associated with lower odds (\cong 0.87) of waking up tired. Free cholesterol, phospholipids and total lipids in medium and large LDL, small very low-density lipoprotein (VLDL) and very small VLDL; and apolipoprotein B and omega-3 fatty acids were associated with lower odds of snoring (\cong 0.90).

4. DISCUSSION

Using data from the SABRE cohort, we show in cross-sectional analysis, that 32 circulating plasma metabolites are associated with distinct sleep quality phenotypes. In particular, metabolites that were associated both with higher as well as lower odds of difficulty falling asleep and snoring were identified. Increased levels of some of the metabolites are associated with lower odds of early morning waking and waking up tired.

Difficulty falling asleep is one of the most frequent symptoms reported by insomnia patients¹⁶. Our results show that increased levels of histidine, isoleucine and valine were associated with lower odds of difficulty falling asleep even after adjusting for the relevant covariates. Interestingly, all three are essential amino acids, which means that

they cannot be synthesized de novo and therefore, may be linked to a deficient diet. Histidine is a precursor of histamine which has been proposed as a regulator of wakefulness¹⁷. Isoleucine and valine are precursors of both glutamate and gamma-butyric acid¹⁸, the main excitatory and inhibitory neurotransmitters. By restoring the inhibition: excitatory ratios, their supplementation could restore normal sleep patterns. In this study, we report that BCCA are associated with lower odds ($\cong 0.90$) of difficulty falling asleep. To date, branched-chain amino acids such as leucine and valine have been successfully trialed to improve sleep quality in certain population groups such as cirrhosis patients¹⁹.

We also observed that in SABRE snoring was associated with 31 metabolites suggesting a potential complex metabolic disturbance. Most of these metabolites are from the lipid profile and include serum lipid extracts (such as DHA, polyunsaturated fatty acids) and cholesterol, cholesterol-esters and phospholipids in small/medium/large LDL and HDL fractions. Although the snoring-insulin resistance and associated dyslipidemia connection has previously been reported⁷, the novelty of this study comes from the detailed lipoprotein analysis which identified specific lipoprotein components. For example, the largest odds ratio for snoring was for cholesterol-esters in medium LDL. Our data show that both higher LDL and HDL associate with lower odds of snoring. The effect of HDL is consistent with the existing literature⁷, but the effect of LDL is not. NMR quantifies lipoproteins based on molecular weight and diameter into the lipoprotein subclasses. Given that HDL and LDL are so tightly correlated (mostly positively) (**Figure 3**), the negative association of LDL with snoring could be due to their tight relationship rather than a true effect. Although an inverse correlation between HDL and LDL is to be expected, it should be noted that lipoproteins in metabolism are in a constant state of flux with complex interactions, rather than discrete measures. Moreover, there is a shift from the traditional thinking that HDL is “good” and LDL is “bad” as there are beneficial subfractions of LDL and detrimental ones of HDL. In addition, the directionality of the associations between snoring, diabetes, WHR and metabolites is still a matter of debate as complex metabolic interactions exist (**Figure 4**).

Lastly, the inverse association between DHA and snoring severity has previously been reported²⁰. Beneficial effects of ω -3 fatty acids in terms of reduced daytime sleepiness have been observed after supplementation in deployed soldiers²¹. DHA is an important component of neural membranes which has been postulated to be both a synaptic and a neuromodulator altering the levels of glutamate, monoamines, acetylcholine and endocannabinoids²².

To the best of our knowledge, we are the first to report acetate, all BCCA and phenylalanine to be associated with snoring. As acetate generates acetyl-CoA, it has been proposed as an epigenetic metabolite to regulate lipid synthesis under hypoxia²³ which can occur during snoring. Phenylalanine is a precursor to dopamine and norepinephrine which have been shown to be downregulated in sleep deprivation²⁴. Interestingly, higher valine has been associated with snoring (higher odds), early morning waking (lower odds) and difficulty falling asleep (lower odds) making it more likely to be a key biological player in regulating sleep. Given the wide-ranging effects, it could be that valine operates within a narrow homeostatic window with higher levels promoting sleep (lower odds of difficulty falling asleep and early waking), but if they are too high snoring could arise. This theory is supported by its involvement in multiple important processes, such as protein synthesis, energy production, glutamate compartmentalization, and indirect control of serotonin, dopamine and noradrenaline neurotransmitter synthesis²⁵.

Our sensitivity analysis revealed that higher creatinine and valine associate with lower odds of early morning waking. A positive relationship between creatinine and long sleep duration has been previously reported²⁶. Creatinine is a breakdown product of creatine phosphate. The latter is of neurophysiological importance acting as an antioxidant, a neuromodulator (of Gamma aminobutyric acid A (GABA_A) and of N-methyl-D-aspartate (NMDA) receptors) and a regulator of neuronal energy metabolism. It has been postulated to neutralize the negative effects of reactive oxygen species which occur on the background of chronic psychological stress²⁷. To date, it has been successfully

tried to improve mood and performance following sleep deprivation²⁸. Its potential for the prevention of early morning waking has not been yet explored in clinical studies.

Waking up tired has been associated with chronic fatigue syndrome. Our sensitivity analysis identified that higher albumin and lactic acid are related to lower odds of waking up tired. Lower albumin correlates with fatigue in chronic kidney disease patients²⁹. We are the first to generalize this association in a large-scale, predominantly healthy cohort. Although we did not specifically measure tryptophan, the observed effect might be mediated by this albumin-bound amino acid, as it has been linked to a higher serotonin: dopamine ratio leading to central, as opposed to peripheral, fatigue³⁰. Serum lactate has previously been reported as a possible sleep/wake biomarker with higher levels during wakefulness; and persistent and sustained decline during nonrapid eye movement sleep³¹. Serum lactate could potentially be extended as a biomarker for the early morning waking phenotype. It could also be that central fatigue may stem from a lower neuronal glucose consumption translating into lower plasma lactate levels.

Strengths of the present study include the broad spectrum of metabolites enabled by NMR metabolomics, large sample size and extensive adjustment for covariates known to affect the relationship between metabolites and sleep. The sample is representative of primary care registration as healthcare services are free nationally in the UK. Limitations to the study include its inherent cross-sectional nature and the failure to capture longitudinal effects or to support causality. The directionality of the associations between metabolites and sleep phenotypes is still a matter of debate and whether metabolites cause or are a consequence of abnormal sleep has yet to be elucidated. In addition, there were only a few women included due to the study design. Another limitation is the long-term storage of samples (over 20 years) before NMR analysis.

5. CONCLUSION

Histidine, leucine and valine associated with lower odds of difficulty falling asleep, while branched chain amino acids were positively associated with snoring. Total cholesterol in

certain HDL and LDL subfractions appeared beneficial in terms of snoring. Although the current evidence is unable to support causality, the identified metabolites could provide a direction for future studies to further understand abnormal sleep patterns.

Funding

SABRE was funded at baseline by the UK Medical Research Council and Diabetes UK. Follow-up studies have been funded by the Wellcome Trust (WT 082464), British Heart Foundation (SP/07/001/23603 and CS/13/1/30327). Metabolomic analyses were funded by Diabetes UK (13/0004774). NC received support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Support has also been provided at follow-up by the North and West London and Central and East London National Institute of Health Research Clinical Research Networks. VG is funded by a joint grant from Diabetes UK and the British Heart Foundation (15/0005250).

Acknowledgements

The authors would like to thank all the SABRE members for their participation and continuous engagement with follow-up and all SABRE scientific and data collection teams.

REFERENCES

1. Fortier-Brochu É, Beaulieu-Bonneau S, Ivers H, Morin CM. Relations between sleep, fatigue, and health-related quality of life in individuals with insomnia. *Journal of Psychosomatic Research* 2010;**69**(5):475-483.
2. Medic G, Wille M, Hemels ME. Short- and long-term health consequences of sleep disruption. *Nature and Science of Sleep* 2017;**9**:151-161.
3. Depner C, Stothard E, Wright K. Metabolic Consequences of Sleep and Circadian Disorders. *Curr Diab Rep* 2014;**14**(7):1-9.
4. Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO. Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. *Diabetes care* 2009;**32**(11):1980.
5. Tillin T, Forouhi NG, McKeigue PM, Chaturvedi N. Southall And Brent REvisited: Cohort profile of SABRE, a UK population-based comparison of cardiovascular disease and diabetes in people of European, Indian Asian and African Caribbean origins. *International Journal of Epidemiology* 2012;**41**(1):33-42.

6. Sharma S, Kavuru M. Sleep and Metabolism: An Overview. *International Journal of Endocrinology* 2010;**2010**(2010).
7. Alexopoulos E, Gletsou E, Kostadima E, Kaditis D, Zakynthinos E, Gourgoulianis K, Kaditis A. Effects of obstructive sleep apnea severity on serum lipid levels in Greek children with snoring. *Sleep Breath* 2011;**15**(4):625-631.
8. Fabian JT, Jan K, Jörg B. Statistical methods for the analysis of high-throughput metabolomics data. *Computational and Structural Biotechnology Journal* 2013;**4**(5):e201301009.
9. Delles C, Rankin NJ, Boachie C, McConnachie A, Ford I, Kangas A, Soininen P, Trompet S, Mooijaart SP, Jukema JW, Zannad F, Ala-Korpela M, Salomaa V, Havulinna AS, Welsh P, Würtz P, Sattar N. Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. *European Journal of Heart Failure* 2018;**20**(4):663-673.
10. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. *Diabetic Medicine* 1998;**15**(7):539-553.
11. Soininen P, Kangas AJ, Würtz P, Tukiainen T, Tynkkynen T, Laatikainen R, Järvelin M-r, Kähönen M, Lehtimäki T, Viikari J, Raitakari OT, Savolainen MJ, Ala-korpela M. High-throughput serum NMR metabolomics for cost-effective holistic studies on systemic metabolism. *The Analyst* 2009;**134**(9):1781-1785.
12. Jenkins CD, Stanton B-A, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. *Journal of Clinical Epidemiology* 1988;**41**(4):313-321.
13. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)* 1995;**57**(1):289-300.
14. He H WW, Crits-Christoph P, Gallop R, Tang W, Chen DD, Tu XM. On the implication of structural zeros as independent variables in regression analysis : applications to alcohol research. In. *J Data Sci*; 2014, 439-460.
15. *The R Programming Language and Software*. In; 2014, 71-117.
16. Lombardero A, Hansen CD, Richie AE, Campbell DG, Joyce AW. A Narrative Review of the Literature on Insufficient Sleep, Insomnia, and Health Correlates in American Indian/Alaska Native Populations. *Journal of Environmental and Public Health* 2019;**2019**.
17. Thakkar MM. Histamine in the regulation of wakefulness. *Sleep Medicine Reviews* 2011;**15**(1):65-74.
18. Sweatt AJ, Garcia-Espinosa MA, Wallin R, Hutson SM. Branched-chain amino acids and neurotransmitter metabolism: expression of cytosolic branched-chain aminotransferase (BCATc) in the cerebellum and hippocampus. *The Journal of comparative neurology* 2004;**477**(4):360.
19. Ichikawa T, Naota T, Miyaaki H, Miuma S, Isomoto H, Takeshima F, Nakao K. Effect of an oral branched chain amino acid-enriched snack in cirrhotic patients with sleep disturbance. *Hepatology Research* 2010;**40**(10):971-978.
20. Ladesich JB, Pottala JV, Romaker A, Harris WS. Membrane level of omega-3 docosahexaenoic acid is associated with severity of obstructive sleep apnea. *Journal of*

clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2011;**7**(4):391.

21. Dretsch M, Johnston D, Bradley R, Macrae H, Deuster P, Harris W. Effects of Omega-3 Fatty Acid Supplementation on Neurocognitive Functioning and Mood in Deployed U.S. Soldiers: A Pilot Study. *Military Medicine* 2014;**179**(4):396-403.
22. Tanaka K, Farooqui AA, Siddiqi NJ, Alhomida AS, Ong W-Y. Effects of docosahexaenoic Acid on neurotransmission. *Biomolecules & therapeutics* 2012;**20**(2):152.
23. Xue G, Shu-Hai L, Feng R, Jin-Tao L, Jia-Jia C, Chuan-Bo Y, Hong-Bin Y, Shu-Xia J, Guo-Quan Y, Di W, Yi W, Ying L, Zongwei C, Ying-Ying X, Jing C, Wenqiang Y, Peng-Yuan Y, Qun-Ying L. Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia. *Nature Communications* 2016;**7**(1).
24. Volkow ND, Tomasi D, Wang G-J, Telang F, Fowler JS, Logan J, Benveniste H, Kim R, Thanos PK, Ferré S. Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2012;**32**(19):6711.
25. Fernstrom JD. Branched-chain amino acids and brain function. *The Journal of nutrition* 2005;**135**(6 Suppl):1539S.
26. Choi H, Kim HC, Lee JY, Lee J-M, Choi DP, Suh I. Sleep duration and chronic kidney disease: The Korean Genome and Epidemiology Study (KoGES)-Kangwha study. *The Korean journal of internal medicine* 2017;**32**(2):323.
27. Allen PJ. Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value? *Neuroscience and biobehavioral reviews* 2012;**36**(5):1442.
28. McMorris T, Harris R, Swain J, Corbett J, Collard K, Dyson R, Dye L, Hodgson C, Draper N. Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol. *Psychopharmacology* 2006;**185**(1):93-103.
29. Jhamb M, Liang K, Yabes J, Steel JL, Dew MA, Shah N, Unruh M. Prevalence and Correlates of Fatigue in Chronic Kidney Disease and End-Stage Renal Disease: Are Sleep Disorders a Key to Understanding Fatigue? *American Journal of Nephrology* 2014;**38**(6):489-495.
30. Meeusen R. Central fatigue - the serotonin hypothesis and beyond. *Journal of Sports Sciences* 2009;**27**:S22.
31. Naylor E, Aillon DV, Barrett BS, Wilson GS, Johnson DA, Johnson DA, Harmon HP, Gabbert S, Petillo PA. Lactate as a biomarker for sleep. *Sleep* 2012;**35**(9):1209.

FIGURE LEGENDS:

Figure 1. Manhattan Plot of associations between Metabolites and Snoring.

Metabolites with a significant association with snoring in Model 2 are annotated

HDL, high-density lipoprotein; s-HDL, small-HDL; m-HDL, medium-HDL; l-HDL, large-HDL, xl-HDL, extra-large HDL; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; s-LDL, small-LDL; m-LDL, medium-LDL; l-LDL, large-LDL; CE, cholesterol-esters; FC, free cholesterol;

Figure 2. Forest plot of odds ratios and 95% confidence intervals of association for metabolites with snoring which were significant in Model 2 (adjusted for age, sex, ethnicity and years of education, waist-hip-ratio, cardiovascular disease, Type 2 Diabetes, hypertension medication, alcohol units and smoking status)

OR, odds ratio; CI, confidence interval.

Other abbreviations as in **Figure 1**.

Figure 3. Correlation matrix of HDL and LDL sub-fractions

Positive correlations are displayed in blue and negative ones are displayed in red. Color intensity and the size of the circle is proportional to correlation coefficients. The legend color displays the correlation coefficients range and the corresponding colors.

Abbreviations as in **Figure 1**.

Figure 4. Directed Acyclic Graph for Snoring

Low HDL, high LDL, high waist-to-hip (WHR) ratio and type 2 diabetes (T2DM) have been shown to be associated with snoring. However, a high WHR is associated with T2DM and both variables are associated with dyslipidemia. This directed acyclic graph highlights the complex interactions which exist within this system.

Abbreviations as in **Figure 1**.

Table 1. Baseline demographic characteristics of Southall And Brent Revisited (SABRE) cohort participants stratified by sleep phenotype status

Sleep phenotype	Difficulty Falling Asleep			Early Morning Waking			Waking Up Tired			Snoring			Overall n=2718
	Yes 453 (16.67)	No 2265 (83.33)	p-value	Yes 1108 (40.77)	No 1610 (59.23)	p-value	Yes 927 (34.11)	No 1791 (65.89)	p-value	Yes 1051 (38.67)	No 1667 (61.33)	p-value	
Age, years	52.08 ± 7.27	52.10 ± 7.16	0.966	52.15 ± 7.11	52.06 ± 7.23	0.709	51.25 ± 7.05	52.53 ± 7.20	<0.0001	52.66 ± 7.01	51.74 ± 7.25	0.001	52.10 ± 7.18
Male sex (%)	361 (79.69)	2018 (89.09)	<0.0001	961 (86.73)	1418 (88.07)	0.327	787 (84.89)	1592 (89.06)	0.004	982 (93.43)	1397 (83.80)	<0.0001	2379 (87.53)
Ethnicity													
European	193 (42.60)	1159 (51.17)	0.002	468 (42.24)	884 (54.91)	<0.0001	456 (49.19)	896 (50.03)	0.528	512 (49.57)	840 (50.39)	0.681	1352 (49.74)
South Asian	238 (52.5)	984 (43.44)		591 (53.34)	631 (39.19)		427 (46.06)	795 (44.39)		481 (45.77)	741 (44.45)		1222 (44.96)
African-Caribbean	22 (0.05)	122 (5.39)		49 (4.42)	95 (5.9)		44 (4.75)	100 (5.58)		58 (4.66)	86 (5.16)		144 (5.30)
Years of education	10.97 ± 3.25	11.25 ± 3.11	0.083	11.11 ± 3.18	11.27 ± 3.11	0.197	11.14 ± 3.27	11.24 ± 3.07	0.461	11.07 ± 3.19	11.29 ± 3.11	0.062	11.21 ± 3.14
Waist-hip-ratio	0.94 ± 0.09	0.94 ±0.08	0.864	0.95 ± 0.08	0.94 ± 0.08	0.0004	0.94 ± 0.09	0.95 ± 0.08	0.546	0.96 ± 0.08	0.93 ± 0.09	<0.0001	0.95 ± 0.08
Cardiovascular disease	59 (13.02)	184 (8.12)	0.001	119 (10.74)	124 (7.70)	0.008	112 (12.08)	131 (7.31)	<0.0001	114 (10.85)	129 (7.74)	0.007	243 (8.94)
Diabetes	72 (15.89)	276 (12.19)	0.038	151 (13.63)	187 (11.62)	0.313	120 (12.95)	228 (12.73)	0.922	152 (14.46)	196 (11.76)	0.046	348 (12.80)
Antihypertensives	80 (17.66)	279 (12.32)	0.003	171 (15.43)	188 (11.68)	0.005	149 (16.07)	210 (11.72)	0.002	165 (15.70)	194 (11.63)	0.003	359 (13.21)

Alcohol consumption, units	12.14 ± 17.63	11.67 ± 15.24	0.601	11.94 ± 15.56	11.62 ± 15.01	0.610	12.15 ± 16.58	11.54 ± 15.16	0.351	12.71 ± 16.78	11.14 ± 14.88	0.013	11.75 ± 15.66
Smoking status													
Never	231 (50.99)	1211 (53.47)	0.008	622 (56.14)	820 (50.93)	0.027	482 (52.00)	960 (48.71)	0.066	518 (49.29)	924 (55.43)	0.006	1442 (53.05)
Ex-smoker	96 (21.19)	568 (25.08)		231 (20.85)	381 (23.66)		232 (25.00)	380 (21.22)		250 (23.79)	362 (21.72)		612 (22.52)
Current smoker	126 (27.82)	486 (21.45)		255 (23.01)	409 (25.41)		213 (23.00)	451 (25.18)		283 (26.92)	381 (22.85)		664 (24.43)

Characteristics of participants stratified by sleep phenotypes. Values are presented as mean ± standard deviation for continuous variables or n (%) for categorical variables. P-values were calculated using t-test for continuous variables or χ^2 -test for categorical variables.

Table 2. Associations between the metabolites who have passed the screening stage and the sleep phenotypes.

Sleep phenotype	Metabolite	Multivariable adjusted Odds Ratios	95% Confidence Interval	p-value
Difficulty Falling Asleep	Histidine	0.89	0.80-0.99	0.033
	Leucine	0.94	0.75-0.96	0.008
	Valine	0.84	0.75-0.94	0.002
Snoring	Acetate	1.11	1.02-1.20	0.015
	Creatinine	0.99	0.91-1.09	0.974
	Glucose	0.98	0.87-1.09	0.705
	Glutamine	0.96	0.89-1.04	0.314
	Glycoprotein Acetyls	1.03	0.94-1.12	0.517
	Isoleucine	1.15	1.04-1.26	0.004
	Lactate	0.98	0.90-1.07	0.671
	Leucine	1.11	1.01-1.21	0.022
	Phosphatidylcholine	0.92	0.85-1.00	0.054
	Phenylalanine	1.16	1.06-1.26	0.0005
	Tyrosine	1.05	0.96-1.15	0.303
	Valine	1.15	1.05-1.25	0.002
	Total cholines	0.92	0.85-0.997	0.017
	Apolipoprotein A-I	0.88	0.81-0.96	0.003
	Docosahexaenoic acid 22:6	0.89	0.82-0.96	0.005
Linoleic acid 18:2	0.93	0.86-1.01	0.097	
Esterified Cholesterol	0.90	0.83-0.96	0.005	

Free Cholesterol	0.91	0.84-0.99	0.027
Total cholesterol in HDL	0.90	0.83-0.99	0.025
Total cholesterol in HDL2	0.91	0.84-0.995	0.038
HDL Diameter	0.96	0.88-1.05	0.431
Total cholesterol in small HDL	0.91	0.84-0.99	0.022
Cholesterol-esters in small HDL	0.91	0.84-0.99	0.032
Triglycerides in small HDL	1.03	0.95-1.13	0.45
Total cholesterol in medium HDL	1.08	0.85-1.00	0.056
Cholesterol-esters in medium HDL	0.92	0.85-1.00	0.063
Free cholesterol in medium HDL	0.92	0.85-0.999	0.049
Lipids in medium HDL	0.92	0.85-1.00	0.056
Concentration of medium HDL particle	0.92	0.85-1.00	0.058
Phospholipids in medium HDL	0.93	0.85-1.01	0.079
Total Cholesterol in large HDL	0.95	0.85-1.06	0.393
Cholesterol-esters in large HDL	0.96	0.89-1.05	0.376
Free cholesterol in large HDL	0.998	0.92-1.08	0.963
Lipids in large HDL	0.95	0.88-1.04	0.266
Concentration of large HDL particle	0.95	0.88-1.04	0.27
Phospholipids in large HDL	0.94	0.87-1.03	0.149
Total Cholesterol in very large HDL	0.94	0.87-1.03	0.180
Cholesterol-esters in very large HDL	0.94	0.87-1.03	0.174
Free cholesterol in very large HDL	0.95	0.88-1.04	0.282
Lipids in very large HDL	0.96	0.88-1.05	0.326
Concentration of very large HDL particle	0.96	0.88-1.05	0.348
Phospholipids in very large HDL	0.98	0.90-1.07	0.655

Free cholesterol in IDL	0.91	0.84-0.99	0.027
Total cholesterol in LDL	0.89	0.82-0.96	0.004
LDL diameter	1.14	1.05-1.23	0.002
Total cholesterol in small LDL	0.87	0.80-0.94	0.0009
Cholesterol-esters in small LDL	0.89	0.82-0.96	0.004
Free cholesterol in small LDL	0.88	0.81-0.96	0.004
Total lipids in small LDL	0.89	0.82-0.96	0.003
Concentration of small LDL particle	0.89	0.82-0.96	0.004
Phospholipids in small LDL	0.90	0.82-0.97	0.009
Total Cholesterol in medium LDL	0.89	0.82-0.96	0.002
Cholesterol-esters in medium LDL	0.64	0.45-0.92	0.016
Free cholesterol in medium LDL	0.90	0.82-0.97	0.005
Total cholesterol in large LDL	0.90	0.83-0.97	0.008
Free cholesterol in large LDL	0.90	0.84-0.98	0.02
Polyunsaturated fatty acids	0.92	0.85-0.997	0.043
Serum cholesterol	0.90	0.83-0.97	0.006
Serum triglycerides	0.95	0.88- 1.03	0.243

All reported analyses here consisted of generalized linear mixed models with binomial distribution and logit link (i.e. logistic regression). Model 2 was adjusted for age, sex, ethnicity and years of education, waist-hip-ratio, cardiovascular disease, Type 2 Diabetes, hypertension medication, alcohol units and smoking status.

HDL, high density lipoprotein; IDL, intermediate-density lipoproteins; LDL, low-density lipoprotein.

Other abbreviations as in **Table 1**




Figure 1. Manhattan Plot of associations between Metabolites and Snoring. Metabolites with a significant association with snoring in Model 2 are annotated

HDL, high-density lipoprotein; s-HDL, small-HDL; m-HDL, medium-HDL; l-HDL, large-HDL; xl-HDL, extra-large HDL; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; s-LDL, small-LDL; m-LDL, medium-LDL; l-LDL, large-LDL; CE, cholesterol-esters; FC, free cholesterol;




Figure 2. Forest plot of odds ratios and 95% confidence intervals of association for metabolites with snoring which were significant in Model 2 (adjusted for age, sex, ethnicity and years of education, waist-hip-ratio, cardiovascular disease, Type 2 Diabetes, hypertension medication, alcohol units and smoking status)

OR, odds ratio; CI, confidence interval.

Other abbreviations as in **Figure 1**.




Figure 3. Correlation matrix of HDL and LDL sub-fractions

Positive correlations are displayed in blue and negative correlations are displayed in red. Color intensity and the size of the circle is proportional to correlation coefficients. The legend color displays the correlation coefficients range and the corresponding colors.

Abbreviations as in **Figure 1**.




Figure 4. Directed Acyclic Graph for Snoring

Low HDL, high LDL, high waist-to-hip (WHR) ratio and type 2 diabetes (T2DM) have been shown to be associated with snoring. However, a high WHR is associated with T2DM and both variables are associated with dyslipidemia. This direct acyclic graph highlights the complex interactions which exist within this system.

Abbreviations as in **Figure 1**.